News for Philogen S.p.A. (PHIL.MI)

Sun Pharma and Philogen partner for global commercialization of innovative anti-cancer immunotherapy Fibromun, aiming to address unmet medical needs.

Pyxis Oncology is an antibody and antibody-drug conjugate developer with initial results from 2 clinical trials ahead in 2024. Read why I rate PYXS stock a buy.

Advanced melanoma is when melanoma cells spread from where they started (the primary melanoma) to other parts of the body. The advanced melanoma...

FIBROSARC is a Phase III trial evaluating Onfekafusp alfa plus doxorubicin versus doxorubicin alone as front-line therapy for patients with advanced or metastatic Soft Tissue Sarcoma An...

Nidlegy™ Phase III PIVOTAL trial meets the study’s primary objective demonstrating statistically significant and clinically meaningful improvement in Recurrence-Free Survival for patients with locally advanced fully resectable melanoma GlobeNewswire October 16, 2023 Intratumoral Nidlegy™ followed by surgery significantly improved the Recurrence-Free Survival compared to surgery alone About Sun Pharmaceutical Industries Ltd. (CIN...

.Sun Pharma and Philogen announce successful Phase III PIVOTAL trial results for Nidlegy in melanoma. Treatment arm showed statistically significant, clinically meaningful improvement in Recurrence-Free Survival (RFS) compared to control arm. 257 patients enrolled across 22 clinical centres in Europe. Nidlegy also undergoing Phase-II trials for high-risk basal cell carcinoma and other skin cancers. Shares down 0.91% at Rs 1,135.9.

Prominent somatostatin analogs market players include Sun Pharmaceutical Industries Limited, Novartis AG, Biodexa Pharmaceuticals PLC, Ipsen Pharma, Pfizer...

The emergence of new products in the pipeline will add to the soft tissue sarcoma market growth in the future. In addition, persistently rising cases of...

Philogen enters into a Service and Supply Agreement with IBSA for the GMP Production of a Therapeutic Protein Siena, Italy, 28th June 2023 – Philogen...